BLRX BioLineRx Ltd. - American Depositary Shares
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Mar 27, 2026
$2.37
· of 52w range
· above low
· to high
$2.1552w low
$4.5652w high
EPS
$0.00
Revenue
$1M
your badges
52W Range
$2–$5
Analyst Rating
·
Price Target
$22
P/E
·
ROE
-12.8%
Net Profit Margin
-171.7%
Your badge strip is empty — pin a metric anywhere on this page.
BLRX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.37
EPS
$0.00
Revenue
$1M
ROE
-12.8%
52W Range
$2–$5
BLRX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Jan. 30, 2025 | 1-for-40 | Reverse |
| July 15, 2019 | 1-for-15 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$1M2021-12-31 → 2025-12-31
EPS$0.002020-12-31 → 2025-12-31
Free Cash Flow$-8M2017-12-31 → 2025-12-31
Net margin-171.7%2023-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | BLRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin | 80.5%5Y avg ≈57.2% | ≈57.2% | · | · | |
| Operating Margin | -871.8%5Y avg ≈-659.2% | ≈-659.2% | · | · | |
| EBITDA Margin | -829.8%5Y avg ≈-640.7% | ≈-640.7% | · | · | |
| Net Profit Margin | -171.7%5Y avg ≈-488.8% | ≈-488.8% | · | · | |
| ROA | -5.1%5Y avg ≈-36.6% | ≈-36.6% | -43.9% | Top tier | |
| ROE | -12.8%5Y avg ≈-74.6% | ≈-74.6% | 70.8% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | BLRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio | 2.05Y avg ≈3.2 | ≈3.2 | 2.9 | Low liquidity | |
| Quick Ratio | 0.15Y avg ≈0.3 | ≈0.3 | 1.5 | Low liquidity | |
| Interest Coverage | -8.25Y avg ≈-14.9 | ≈-14.9 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | BLRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.2 | ≈0.2 | · | · | |
| Inventory Turnover | 0.15Y avg ≈2.5 | ≈2.5 | · | · | |
| Revenue / Employee | ≈$59.0K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-47.1%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-0.77 | — | — | |
| Sept. 30, 2024 | $-0.07 | — | — | |
| March 31, 2024 | $-0.01 | — | — | |
| Sept. 30, 2023 | $-0.30 | — | — | |
| Sept. 30, 2015 | $-0.12 | $-0.08 | -47.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $1M | $29M | $5M | $0 | $0 | |
| Cost of Revenue | $230.0K | $9M | $4M | $0 | $0 | |
| Gross Profit | $950.0K | $20M | $1M | $0 | $0 | |
| R&D Expense | $8M | $9M | $13M | $18M | $19M | |
| SG&A Expense | $3M | $6M | $6M | $5M | $4M | |
| Operating Income | $-10M | $-20M | $-50M | $-29M | $-25M | |
| Interest Expense | $1M | $9M | $2M | $2M | $984.0K | |
| Interest Income | $1M | $2M | $2M | $694.0K | $559.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-2M | $-9M | $-61M | $-25M | $-27M | |
| EPS (Basic) | $0.00 | $-0.01 | $-0.06 | $-0.03 | $-0.04 | |
| EPS (Diluted) | $0.00 | $-0.01 | $-0.06 | $-0.03 | $-0.04 | |
| Shares (Basic) | 2,465,272,604 | 1,198,107,761 | 963,365,525 | 773,956,973 | 662,933,695 | |
| Shares (Diluted) | 2,465,272,604 | 1,198,107,761 | 963,365,525 | · | · | |
| EBITDA | $-10M | $-20M | $-49M | $-29M | $-24M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $632.0K | $944.0K | $3M | $4M | $8M | |
| Inventory | $2M | $3M | $2M | $0 | · | |
| Current Assets | $24M | $27M | $47M | $52M | $57M | |
| PP&E (Net) | $160.0K | $386.0K | $473.0K | $726.0K | $952.0K | |
| Intangibles | $16M | $10M | $15M | $22M | $22M | |
| Total Assets | $41M | $39M | $64M | $76M | $81M | |
| Current Liabilities | $12M | $15M | $43M | $11M | $10M | |
| Total Liabilities | $18M | $25M | $51M | $26M | $13M | |
| Retained Earnings | $-401M | $-400M | $-391M | $-330M | $-305M | |
| Stockholders' Equity | $18M | $13M | $13M | $51M | $68M |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| D&A | $495.0K | $431.0K | $583.0K | $615.0K | $660.0K | |
| Other Non-cash | $-7M | $-35M | $37M | $-2M | $3M | |
| Operating Cash Flow | $-8M | $-44M | $-23M | $-26M | $-24M | |
| CapEx | $25.0K | $53.0K | $116.0K | $131.0K | $97.0K | |
| Investing Cash Flow | $-9M | $29M | $1M | $4M | $-38M | |
| Financing Cash Flow | $9M | $21M | $15M | $20M | $58M | |
| Free Cash Flow | $-8M | $-44M | $-23M | $-26M | $-24M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 80.5% | 68.0% | 23.1% | · | · | |
| Operating Margin | -871.8% | -70.5% | -1035.3% | · | · | |
| Net Margin | -171.7% | -31.9% | -1262.8% | · | · | |
| EBITDA Margin | -829.8% | -69.0% | -1023.2% | · | · | |
| ROA | -5.1% | -17.9% | -86.4% | -31.6% | -42.0% | |
| ROE | -12.8% | -69.1% | -189.2% | -42.0% | -60.0% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 1.8 | 1.5 | 4.9 | 5.9 | |
| Quick Ratio | 0.1 | 0.1 | 0.1 | 0.3 | 0.9 | |
| Interest Coverage | -8.2 | -2.2 | -23.2 | -16.3 | -24.6 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.6 | 0.1 | · | · | |
| Inventory Turnover | 0.1 | 3.6 | 3.8 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue / Share | $0.00 | · | · | · | · | |
| Cash Flow / Share | $-0.00 | · | · | · | · | |
| EPS (TTM) | $0.00 | $-0.01 | $-0.06 | $-0.03 | $-0.04 |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue TTM | $1M | $29M | $5M | $0 | $0 | |
| Net Income TTM | $-2M | $-9M | $-61M | $-25M | $-27M | |
| P/E | · | -840.0 | -1046.7 | -786.7 | -2040.0 | |
| Earnings Yield | 0.00% | -0.12% | -0.10% | -0.13% | -0.05% |
Per Share
| Metric | Trend | Q4 2025 | Q4 2021 | Q4 2018 | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2013 | Q4 2012 | Q4 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS (TTM) | $0.00 | $-0.04 | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | Q4 2025 | Q4 2021 | Q4 2018 | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2013 | Q4 2012 | Q4 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1M | $0 | · | · | · | · | · | · | · | |
| Net Income TTM | $-2M | $-27M | $-23M | $-16M | $-14M | · | · | · | · | |
| P/E | · | -2040.0 | · | · | · | · | · | · | · | |
| Earnings Yield | 0.00% | -0.05% | · | · | · | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $1M | $29M | $5M | $0 | $0 |
| Gross Margin % | 80.5% | 68.0% | 23.1% | · | · |
| Operating Margin % | -871.8% | -70.5% | -1035.3% | · | · |
| Net Income | $-2M | $-9M | $-61M | $-25M | $-27M |
| Diluted EPS | $0.00 | $-0.01 | $-0.06 | $-0.03 | $-0.04 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 2.0 | 1.8 | 1.5 | 4.9 | 5.9 |
| Quick Ratio | 0.1 | 0.1 | 0.1 | 0.3 | 0.9 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-8M | $-44M | $-23M | $-26M | $-24M |
Institutional owners (13F) 15 filers · $329K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
15
Value held
$329K
New positions
4
Exited positions
3
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 4 (+2 vs prior Q) | 3 (+1 vs prior Q) | 3 (+2 vs prior Q) | 4 (+1 vs prior Q) | +76K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $120,900 | 39,000 | 36.79% | Call option |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $95,824 | 30,911 | 29.16% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $48,085 | 15,412 | 14.63% | Shares |
| CITADEL ADVISORS LLC | $45,868 | 14,796 | 13.96% | Shares |
| RHUMBLINE ADVISERS | $7,679 | 2,478 | 2.34% | Shares |
| WELLS FARGO & COMPANY/MN | $6,240 | 2,000 | 1.90% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $1,550 | 500 | 0.47% | Shares |
| Banque Cantonale Vaudoise | $1,000 | 1 | 0.30% | Shares |
| Nemes Rush Group LLC | $780 | 250 | 0.24% | Shares |
| UBS Group AG | $315 | 101 | 0.10% | Shares |
| NewEdge Advisors, LLC | $256 | 82 | 0.08% | Shares |
| OSAIC HOLDINGS, INC. | $81 | 26 | 0.02% | Shares |
| SBI Securities Co., Ltd. | $31 | 10 | 0.01% | Shares |
| DANSKE BANK A/S | $6 | 2 | 0.00% | Shares |
| CITIGROUP INC | $3 | 1 | 0.00% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Hong Seng Technology Limited, Lepu (Hong Kong) Co., Limited, Lepu Holdings Limited, Lepu Medical (Europe) Cooperatief U.A., Lepu Medical Technology (Beijing) Co., Ltd. | Oct. 26, 2023 | · | Initial filing | · | SEC |
| BIOTECHNOLOGY VALUE FUND, L.P., BIOTECHNOLOGY VALUE FUND II, L.P., BIOTECHNOLOGY VALUE TRADING FUND OS LP, BVF PARTNERS OS LTD., BVF PARTNERS L.P., BVF INC., MARK N. LAMPERT ×2 filings | March 1, 2019 | · | Initial filing | · | SEC |
| PAN ATLANTIC BANK AND TRUST LIMITED, FCMI FINANCIAL CORPORATION, ALBERT D. FRIEDBERG ×8 filings | March 8, 2017 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
BLRX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
2 analysts · 2026-10-02Mean target $22.00 +828.3%
← Below all targets
Current price $2.37
Low$18.00
Mean$22.00
High$26.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| BLRX | · | · | · | -171.7% | -12.8% | 80.5% |
| PLRZ | $14M | 1.7 | · | · | -25.4% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 20-F/A filed Mar 27, 2026